NICE Agrees With FDA in Pulling Avastin's Indication for Metastatic Breast Cancer
February 23, 2011
NICE Agrees With FDA in Pulling Avastin's Indication for Metastatic Breast Cancer
According to the final guidance issued by NICE this week, it appears that the drug sponsor did not submit data to the appraisal committee on biomarkers to stratify best responders to Avastin.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
June 29, 2011 / Pharmacogenomics Reporter - Despite PGx Leads, Avastin Access Debate Not Focused on Personalized Medicine Strategies
August 25, 2010 / Pharmacogenomics Reporter - Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
August 1, 2012 / Pharmacogenomics Reporter - Genentech Gets Public Hearing on Avastin, but Remains Coy on Discussing PGx Data
March 2, 2011 / Pharmacogenomics Reporter - Will Genentech Embrace PGx in Appeal of FDA Decision to Revoke Approval of Avastin in Breast Cancer?
December 22, 2010 / Pharmacogenomics Reporter